Isocitrate dehydrogenase (IDH)2 R140Q mutation induces myeloid and lymphoid neoplasms in mice

Leukemia

Volumn 28, Issue 6, 2014, Pages 1343-1346

  Mylonas, E ^a,b   Janin, M ^a,c   Bawa, O ^d   Opolon, P ^d   David, M ^a,b   Quivoron, C ^a,b   Bernard, O A ^a,b   Ottolenghi, C ^a,c   Debotton, S ^a,b   Penard Lacronique, V ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; FLUOROURACIL; ISOCITRATE DEHYDROGENASE 2; TRANSCRIPTION FACTOR HOXA9;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; BONE MARROW TRANSPLANTATION; CELL DIFFERENTIATION; DISEASE COURSE; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC CELL; LETTER; LEUKOCYTOSIS; LYMPHOMA; MEGAKARYOCYTE; MOUSE; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; ONCOGENE N RAS; PRIORITY JOURNAL; SPLENOMEGALY; STEM CELL; T CELL LYMPHOMA; THROMBOCYTOPENIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONTROLLED STUDY; ERYTHROLEUKEMIA; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHATIC LEUKEMIA; MITOSIS RATE; POINT MUTATION;

ANIMALS; CELLS, CULTURED; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELLS; HUMANS; ISOCITRATE DEHYDROGENASE; LYMPHOCYTES; MICE; MUTATION; MYELOID CELLS; RETROVIRIDAE;

EID: 84902081078     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.18     Document Type: Letter

References (14)

1. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM et al. Cancer-Associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 462: 739-744.
2. Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG et al. Cancerassociated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 2010; 207: 339-344.
3. DiNardo CD, Propert KJ, Loren AW, Paietta E, Sun Z, Levine RL et al. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood 2013; 121: 4917-4924.
4. Janin M, Mylonas E, Saada V, Micol JB, Renneville A, Quivoron C et al. Serum 2-hydroxyglutarate production in IDH1-And IDH2-mutated de novo acute myeloid leukemia: A study by the Acute Leukemia French Association Group. J Clin Oncol 2014; 32: 297-305.
5. Losman JA, Kaelin WG. What a difference a hydroxyl makes: Mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev 2013; 27: 836-852.
6. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010; 18: 553-567.
7. Lu C, Venneti S, Akalin A, Fang F, Ward PS, Dematteo RG et al. Induction of sarcomas by mutant IDH2. Genes Dev 2013; 27: 1986-1998.
8. Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 2013; 340: 626-630.
9. Losman JA, Looper RE, Koivunen P, Lee S, Schneider RK, McMahon C et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 2013; 339: 1621-1625.
10. Wang F, Travins J, DeLaBarre B, Penard-Lacronique V, Schalm S, Hansen E et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 2013; 340: 622-626.
11. Sasaki M, Knobbe CB, Munger JC, Lind EF, Brenner D, Brustle A et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 2012; 488: 656-659.
12. Chen C, Liu Y, Lu C, Cross JR, Morris 4th JP, Shroff AS et al. Cancer-Associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. Genes Dev 2013; 27: 1974-1985.
13. Chaturvedi A, Araujo Cruz MM, Jyotsana N, Sharma A, Yun H, Gorlich K et al. Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood 2013; 122: 2877-2887.
14. Cairns RA, Iqbal J, Lemonnier F, Kucuk C, de Leval L, Jais JP et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood 2012; 119: 1901-1903.